Power3 Medical Products, Inc. (OTCBB:PWRM.OB)
Power3 Medical Products, Inc. (OTC.BB:PWRM), a leading proteomics company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases, delivered four poster presentations at the 2010 International Conference on Alzheimer�s Disease (ICAD) in Honolulu, Hawaii. These presentations discussed NuroPro, Power3�s diagnostic test, and focused on Power3�s Alzheimer�s disease blood serum biomarkers, test and clinical validation trials.
Power3 has filed several patent applications for its NuroPro technology that are currently pending. Power3 also has a world-wide exclusive license from the Baylor College of Medicine in Houston, Texas. To date, Power3 has given 9 presentations on NuroPro at international scientific meetings in the United States, Europe and China, and has published 6 articles in peer-reviewed scientific journals on the subject. Power3 intends to publish these latest findings as well.
Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer�s disease, Parkinson�s disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig�s disease). Power3 applies proprietary methodologies to discover and identify protein biomarkers associated with diseases. Through these processes, Power3 has developed a portfolio of products including BC-SeraPro, a proteomic blood serum test for the early detection of breast cancer for which it has completed Phase I clinical trials, and NuroPro, a proteomic blood serum test for the detection of neurodegenerative diseases, including Alzheimer�s, Parkinson�s and ALS diseases, for which it is currently engaged in Phase II clinical trials. These tests are designed to analyze an individual�s proteins to detect the presence of disease, a patient�s disease progression, a patient�s response to a particular drug, and the mechanisms of disease present in the patient for optimal targeted therapy.
________
Zoltek Companies, Inc. (NasdaqGS: ZOLT)
MARK WEBBER has a lot to thank tiny strands of carbon for. When his Formula 1 car cartwheeled in a spectacular 306kph (190mph) crash at the recent Valencia Grand Prix, what helped him to escape unscathed was the immensely strong carbon-fibre �tub� that racing drivers now sit in. Carbon fibre is an expensive alternative to making things in steel or aluminium, but besides being extremely strong it is also very light. It is found in high-performance parts, like aircraft wings, bits of supercars and the frames of pricey mountain bikes. But if work by Germany�s BMW proves successful, it could also become the material of choice to mass-produce electric cars.
________
The Zweig Fund, Inc. (NYSE:ZF) announced that its third quarterly distribution for 2010 will be $0.086 per share, payable on October 15, 2010, to shareholders of record on October 08, 2010 (ex-date October 06, 2010).
The distribution represents a cash dividend yield of 10% on an annualized basis. Distributions may represent earnings from net investment income, capital gains, excess gains taxable as ordinary income or, if necessary, return of capital. The tax status of the Fund’s distributions is determined at the end of the taxable year.
The Zweig Fund, Inc. is a closed-end fund with an objective of increasing capital primarily through investment in equity securities consistent with the preservation of capital and reduction of risk as determined by the fund’s investment adviser. The Zweig closed-end funds are advised by Zweig Advisers LLC. For more information on the Fund, please contact shareholder services at 800.272.2700 or visit us on the web at www.virtus.com
__________
Zygo Corporation (NASDAQ:ZIGO), a worldwide supplier of optical metrology instruments and high precision optical systems, recently announced that its Metrology Solutions Division has received orders for $3.5 million for large aperture laser interferometer systems from leading Chinese optical research and manufacturing organizations. The large aperture interferometers include systems capable of measuring up to 32 inch (800 millimeter) diameter parts and another capable of 18 inch (450 millimeter) diameter components, along with an upgrade of an existing Zygo 24 inch (600 millimeter) interferometer system. These instruments will be used for the development and manufacture of very large dimensioned optical components and systems, enabling precision surface shape and glass homogeneity measurements.
“These orders are especially gratifying because selection was based on exhaustive technical evaluations focused on achieving the highest level of performance possible. As a world leader of large aperture laser interferometer systems, Zygo’s decades of expertise combined with its unique in-house optical fabrication and metrology portfolio enabled us to package specific solutions required by our customers to help advance their research and manufacturing capabilities,” commented Dan Musinski, Senior Product Manager.
No comments:
Post a Comment